Literature DB >> 7665588

Ubiquitin-mediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation.

A Orian1, S Whiteside, A Israël, I Stancovski, A L Schwartz, A Ciechanover.   

Abstract

In most cases, the transcriptional factor NF-kappa B is a heterodimer consisting of two subunits, p50 and p65, which are encoded by two distinct genes of the Rel family. p50 is translated as a precursor of 105 kDa. The C-terminal domain of the precursor is rapidly degraded, forming the mature p50 subunit consisted of the N-terminal region of the molecule. The mechanism of generation of p50 is not known. It has been suggested that the ubiquitin-proteasome system is involved in the process; however, the specific enzymes involved and the mechanism of limited proteolysis, in which half of the molecule is spared, have been obscure. Palombella and colleagues (Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785) have shown that ubiquitin is required for the processing in a cell-free system of a truncated, artificially constructed, 60-kDa precursor. They have also shown that proteasome inhibitors block the processing both in vitro and in vivo. In this study, we demonstrate reconstitution of a cell-free processing system and demonstrate directly that: (a) the ubiquitin-proteasome system is involved in processing of the intact p105 precursor, (b) conjugation of ubiquitin to the precursor is an essential intermediate step in the processing, (c) the recently discovered novel species of the ubiquitin-carrier protein, E2-F1, that is involved in the conjugation and degradation of p53, is also required for the limited processing of the p105 precursor, and (d) a novel, approximately 320-kDa species of ubiquitin-protein ligase, is involved in the process. This novel enzyme is distinct from E6-AP, the p53-conjugating ligase, and from E3 alpha, the "N-end rule" ligase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665588     DOI: 10.1074/jbc.270.37.21707

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Relationships between proteasomes and viral gene products.

Authors:  A S Jarrousse; K Gautier; S Apcher; S Badaoui; G Boissonnet; M H Dadet; L Henry; J P Bureau; H P Schmid; F Petit
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

2.  Modulation of CRX transactivation activity by phosducin isoforms.

Authors:  X Zhu; C M Craft
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

3.  SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase.

Authors:  A Orian; H Gonen; B Bercovich; I Fajerman; E Eytan; A Israël; F Mercurio; K Iwai; A L Schwartz; A Ciechanover
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 4.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

5.  Isolation of ubiquitin-E2 (ubiquitin-conjugating enzyme) complexes from erythroleukaemia cells using immunoaffinity techniques.

Authors:  K Takada; T Hirakawa; H Yokosawa; Y Okawa; H Taguchi; K Ohkawa
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

6.  Substrate affinity and substrate specificity of proteasomes with RNase activity.

Authors:  Karine Gautier-Bert; Bertrand Murol; Anne-Sophie Jarrousse; Lionel Ballut; Saloua Badaoui; Frank Petit; Hans-Peter Schmid
Journal:  Mol Biol Rep       Date:  2003-03       Impact factor: 2.316

7.  Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism.

Authors:  Benjamin Mordmüller; Daniel Krappmann; Meral Esen; Elmar Wegener; Claus Scheidereit
Journal:  EMBO Rep       Date:  2003-01       Impact factor: 8.807

8.  Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.

Authors:  I Alkalay; A Yaron; A Hatzubai; A Orian; A Ciechanover; Y Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Variants in TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3 interact to confer risk of systemic lupus erythematosus in Chinese population.

Authors:  Xian-Bo Zuo; Yu-Jun Sheng; Su-Juan Hu; Jin-Ping Gao; Yang Li; Hua-Yang Tang; Xian-Fa Tang; Hui Cheng; Xian-Yong Yin; Lei-Lei Wen; Liang-Dan Sun; Sen Yang; Yong Cui; Xue-Jun Zhang
Journal:  Rheumatol Int       Date:  2013-10-04       Impact factor: 2.631

10.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.